Three Novel Myeloma Therapies
Three Novel Myeloma Therapies image
Apr 24, 2021 / 12:00PM - 01:35PM EDT
HealthTree Round Tables for Multiple Myeloma Chapter

Event Description

Three new drug treatments have been added to the treatment arsenal for myeloma, two recently approved by the U.S. Food and Drug Administration (FDA) and one for other cancers is now being studied in phase 3 clinical trials.  Three myeloma experts who participated in clinical trials for each one will discuss each treatment in detail and answer questions submitted by registered viewers.

Schedule & Agenda

person
Three Novel Myeloma Therapies
12:00PM
Jennifer Ahlstrom
Welcome and Introduction of Faculty
person
Three Novel Myeloma Therapies
12:05PM
Jonathan Kaufman, MD
Venetoclax
person
Three Novel Myeloma Therapies
12:20PM
Peter Voorhees, MD
Melflufen
person
Three Novel Myeloma Therapies
12:35PM
Michaela Liedtke, MD
Ide-cel CAR T
person
Three Novel Myeloma Therapies
12:50PM
Full Faculty
Audience Questions and Answers

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Read Bio
The panelist Peter Voorhees, MD
Peter Voorhees, MD

Peter Voorhees, MD, is Director of Outreach and Clinical Operations for Hematologic Malignancies and a Member of the Plasma Cells Disorder Program at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees is an internationally recognized thought leader in multiple myeloma whose research focuses on the clinical development of novel therapeutic strategies for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. He is board certified in Hematology and a member of the American Society of Hematology, American Society of Clinical Oncology and International Myeloma Working Group. He is also a member of the Multiple Myeloma Committee of the Alliance Cooperative Group. He has published numerous original articles, reviews and book chapters in multiple myeloma. He received his medical degree from the University of Michigan, continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and completed a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Prior to joining the Levine Cancer Institute, he was an Associate Professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill where he led their Multiple Myeloma Program.

Read Bio
The panelist Jonathan Kaufman, MD
Jonathan Kaufman, MD

Jonathan Kaufman, MD, is Associate Professor and Associate Vice-Chair for Quality and Safety of the Department of Hematology and Medical Oncology at the Emory University School of Medicine. Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant. His research focus is on the development of optimal treatment regimens and new drug development for patients with plasma cell disorders. Additionally, Dr. Kaufman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with American Society of Clinical Oncology and American Society of Hematology. Dr. Kaufman earned his Medical Degree from the Medical College of Georgia in Augusta. He subsequently completed his Residency in Internal Medicine and his Fellowship in Hematology and Oncology at Emory University.

Read Bio
The panelist Greg Brozeit
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Read Bio
The panelist Michaela Liedtke, MD
Michaela Liedtke, MD

Michaela Liedtke, MD, is Associate Professor of Medicine (Hematology) at the Stanford University Medical Center in Palo Alto, CA and Co-Director of the Stanford Amyloid Center. She treats multiple myeloma, amyloidosis, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and other hematological malignancies. Dr. Liedtke has been an investigator in a number of myeloma-related clinical trials including CAR T therapies, novel therapies for relapsed/refractory disease, disease status with cardiac issues, and plasma cell leukemia. She is a member of the National Comprehensive Cancer Network (NCCN) panel that publishes and updates myeloma treatment guidelines. Dr. Liedtke served in fellowships at Stanford and Memorial Sloan-Kettering Cancer Center in New York, NY. She completed her medical residency at the Albert Einstein College of Medicine in New York, NY and earned her medical degree at the Medizinische Hochschule Hannover, Germany.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811